Pseudomonas aeruginosa (P. aeroginosa) is one of the opportunistic pathogens, which is the main cause of prevalent hospital infections worldwide. The aim of this study was to determine the prevalence of antibiotic resistance pattern against P. aeroginosa from clinical samples in our population. This study was performed during March 2009 to September 2011. During this period 233 clinical isolated samples from hospital patients were examined. In these studies, different strains of P. aeroginosa were isolated from samples, then microbiologically tested. Bacterial susceptibility was performed by the disc-diffusion tests with Kirby Baur disc diffusion tests in Muller-Hinto environment. Our results showed maximum antibiotic resistance (99.5%) of P. aeruginosa against Trimetoprime Solfametoxasole and Ciprofloxacin (55.33%), Amikacin (61%), Imipenem (33%), which were identified as the most effective antibiotics in this study. In conclusion, indeed most Pseudomonas aeruginosa strains infections are treated as soon as possible due to their severe resistance against antibiotics. So, we have to apply an accurate antibiotic treatment discipline, according to the finding, based on antibiogram, in order to prevent its spread and also, monitoring and optimization of antimicrobial use should be considered carefully.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.